Skip to main content
Fig. 7 | Clinical Epigenetics

Fig. 7

From: Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

Fig. 7

Treatment with MS023 renders PARPi-resistant PEO4 ovarian adenocarcinoma cells sensitive to BMN-673. a, b Cell viability curves from PEO1 (a) and PEO4 (b) cells treated with a range of BMN-673 (3.75–60 nM) alone, or in combination with 0.125, 0.25, 0.5, or 1 µM MS023. c, d The open-source R package SynergyFinder was used to visualize the dose–response of the combination of BMN-673 and MS023 in PEO1 (c) and PEO4 (d) cells and to calculate Bliss synergy scores. The Bliss synergy score is presented on the z-axis of the Bliss graph and is used to determine concentrations at which synergy occurs. e Cell viability curves from PEO1 (red) and PEO4 (blue) cells treated with a range of BMN-673 (3.75–60 nM) alone, or in combination with 1 µM MS023

Back to article page